301 - Oral Abstract Session
Antibody Mediated Rejection 1 (Videos Available)

Monday July 02, 2018 | 08:30 to 09:30
Room: N-102
Track: Kidney


Dr. Yassine Bouatou, France
Defining response to standard of care treatment of kidney recipients with antibody-mediated rejection: Role of C1q-binding donor-specific anti-HLA antibodies

Mr. Deng RongHai, P.R. China
The role of donor-derived cell-free dna in the identification of injury in kidney allografts with antibody-mediated rejection or de novo dsa: A pilot study (Video Available)

Prof. Carmen Lefaucheur, France
C1q-binding donor-specific anti-HLA antibodies for clinical decision making in kidney recipients with antibody-mediated rejection receiving standard of care treatment (Video Available)

Mr. Daniel Burguete, United States
Is Banff 2013 classification of renal allograft pathology superior to 2007 Banff in detecting and managing cases of antibody-mediated rejection? (Video Available)

Prof. Nurhan Ozdemir, Turkey
Significance of antibody-mediated vascular rejection (AMVR) on graft survival: Correlation with pure antibody-mediated rejection (AMR)

Prof. Handan Ozdemir, Turkey
Divergent role of programmed death –Lig and 1 (PD-L1) in renal allografts with antibody-mediated rejection (AMR)

© 2022 TTS2018